COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

被引:143
作者
Chi, Wei-Yu [1 ]
Li, Yen-Der [2 ]
Huang, Hsin-Che [3 ]
Chan, Timothy En Haw [4 ,5 ,6 ]
Chow, Sih-Yao [7 ]
Su, Jun-Han [2 ]
Ferrall, Louise [8 ]
Hung, Chien-Fu [8 ,9 ,10 ]
Wu, T-C [8 ,9 ,10 ,11 ,12 ]
机构
[1] Weill Cornell Med, Physiol Biophys & Syst Biol Grad Program, New York, NY USA
[2] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA
[3] Mem Sloan Kettering Canc Ctr, Triinst PhD Program Chem Biol, 1275 York Ave, New York, NY 10021 USA
[4] Max Planck Inst Immunobiol & Epigenet, Int Max Planck Res Sch Immunobiol Epigenet & Meta, Freiburg, Germany
[5] Univ Freiburg, Med Ctr, Dept Urol, Freiburg, Germany
[6] Univ Freiburg, Fac Biol, Freiburg, Germany
[7] EirGenix Inc, Downstream Proc Sci, Hsinchu, Taiwan
[8] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21218 USA
[9] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21218 USA
[10] Johns Hopkins Univ, Dept Obstet & Gynecol, Baltimore, MD 21218 USA
[11] Johns Hopkins Univ, Dept Microbiol & Immunol, Baltimore, MD 21218 USA
[12] Johns Hopkins Med Inst, CRB 2 Room 309,1550 Orleans St, Baltimore, MD 21231 USA
关键词
COVID-19; Vaccine; Immunity; Variant; SARS-CoV-2; MESSENGER-RNA; BNT162B2; VACCINE; CHADOX1; NCOV-19; NEUTRALIZING ANTIBODY; OMICRON VARIANT; NON-INFERIORITY; UNITED-STATES; SINGLE-BLIND; IMMUNOGENICITY; SAFETY;
D O I
10.1186/s12929-022-00853-8
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Coronavirus Disease 2019 (COVID-19) has been the most severe public health challenge in this century. Two years after its emergence, the rapid development and deployment of effective COVID-19 vaccines have successfully controlled this pandemic and greatly reduced the risk of severe illness and death associated with COVID-19. However, due to its ability to rapidly evolve, the SARS-CoV-2 virus may never be eradicated, and there are many important new topics to work on if we need to live with this virus for a long time. To this end, we hope to provide essential knowledge for researchers who work on the improvement of future COVID-19 vaccines. In this review, we provided an up-to-date summary for current COVID-19 vaccines, discussed the biological basis and clinical impact of SARS-CoV-2 variants and subvariants, and analyzed the effectiveness of various vaccine booster regimens against different SARS-CoV-2 strains. Additionally, we reviewed potential mechanisms of vaccine-induced severe adverse events, summarized current studies regarding immune correlates of protection, and finally, discussed the development of next-generation vaccines.
引用
收藏
页数:27
相关论文
共 291 条
[51]   Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021 [J].
Campbell, Finlay ;
Archer, Brett ;
Laurenson-Schafer, Henry ;
Jinnai, Yuka ;
Konings, Franck ;
Batra, Neale ;
Pavlin, Boris ;
Vandemaele, Katelijn ;
Van Kerkhove, Maria D. ;
Jombart, Thibaut ;
Morgan, Oliver ;
de Waroux, Olivier le Polain .
EUROSURVEILLANCE, 2021, 26 (24) :1-6
[52]   BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection [J].
Cao, Yunlong ;
Yisimayi, Ayijiang ;
Jian, Fanchong ;
Song, Weiliang ;
Xiao, Tianhe ;
Wang, Lei ;
Du, Shuo ;
Wang, Jing ;
Li, Qianqian ;
Chen, Xiaosu ;
Yu, Yuanling ;
Wang, Peng ;
Zhang, Zhiying ;
Liu, Pulan ;
An, Ran ;
Hao, Xiaohua ;
Wang, Yao ;
Feng, Rui ;
Sun, Haiyan ;
Zhao, Lijuan ;
Zhang, Wen ;
Zhao, Dong ;
Zheng, Jiang ;
Yu, Lingling ;
Li, Can ;
Zhang, Na ;
Wang, Rui ;
Niu, Xiao ;
Yang, Sijie ;
Song, Xuetao ;
Chai, Yangyang ;
Hu, Ye ;
Shi, Yansong ;
Zheng, Linlin ;
Li, Zhiqiang ;
Gu, Qingqing ;
Shao, Fei ;
Huang, Weijin ;
Jin, Ronghua ;
Shen, Zhongyang ;
Wang, Youchun ;
Wang, Xiangxi ;
Xiao, Junyu ;
Xie, Xiaoliang Sunney .
NATURE, 2022, 608 (7923) :593-+
[53]   A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations [J].
Chakraborty, Chiranjib ;
Sharma, Ashish Ranjan ;
Bhattacharya, Manojit ;
Lee, Sang-Soo .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[54]  
Chan B, 2021, ONTARIO COVID 19 SCI
[55]   Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France [J].
Charmet, Tiffany ;
Schaeffer, Laura ;
Grant, Rebecca ;
Galmiche, Simon ;
Cheny, Olivia ;
Von Platen, Cassandre ;
Maurizot, Alexandra ;
Rogoff, Alexandra ;
Omar, Faiza ;
David, Christophe ;
Septfons, Alexandra ;
Cauchemez, Simon ;
Gaymard, Alexandre ;
Lina, Bruno ;
Lefrancois, Louise H. ;
Enouf, Vincent ;
van der Werf, Sylvie ;
Mailles, Alexandra ;
Levy-Bruhl, Daniel ;
Carrat, Fabrice ;
Fontanet, Arnaud .
LANCET REGIONAL HEALTH-EUROPE, 2021, 8
[56]   mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar [J].
Chemaitelly, Hiam ;
Yassine, Hadi M. ;
Benslimane, Fatiha M. ;
Al Khatib, Hebah A. ;
Tang, Patrick ;
Hasan, Mohammad R. ;
Malek, Joel A. ;
Coyle, Peter ;
Ayoub, Houssein H. ;
Al Kanaani, Zaina ;
Al Kuwari, Einas ;
Jeremijenko, Andrew ;
Kaleeckal, Anvar Hassan ;
Latif, Ali Nizar ;
Shaik, Riyazuddin Mohammad ;
Abdul Rahim, Hanan F. ;
Nasrallah, Gheyath K. ;
Al Kuwari, Mohamed Ghaith ;
Al Romaihi, Hamad Eid ;
Al-Thani, Mohamed H. ;
Al Khal, Abdullatif ;
Butt, Adeel A. ;
Bertollini, Roberto ;
Abu-Raddad, Laith J. .
NATURE MEDICINE, 2021, 27 (09) :1614-+
[57]   THE VACCINE-ADVERSE-EVENT-REPORTING-SYSTEM (VAERS) [J].
CHEN, RT ;
RASTOGI, SC ;
MULLEN, JR ;
HAYES, SW ;
COCHI, SL ;
DONLON, JA ;
WASSILAK, SG .
VACCINE, 1994, 12 (06) :542-550
[58]   Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination [J].
Cheng, Samuel M. S. ;
Mok, Chris Ka Pun ;
Leung, Yonna W. Y. ;
Ng, Susanna S. ;
Chan, Karl C. K. ;
Ko, Fanny W. ;
Chen, Chunke ;
Yiu, Karen ;
Lam, Bosco H. S. ;
Lau, Eric H. Y. ;
Chan, Ken K. P. ;
Luk, Leo L. H. ;
Li, John K. C. ;
Tsang, Leo C. H. ;
Poon, Leo L. M. ;
Hui, David S. C. ;
Peiris, Malik .
NATURE MEDICINE, 2022, 28 (03) :486-+
[59]  
Cho D, 2021, EUA AMENDMENT SUPPOR
[60]  
Cho D, 2021, ASSESSMENT BOOSTER D